Anagliptin vs Vildagliptin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline

Anagliptin · Suiny

Marketed by Sanwa Kagaku Kenkyusho and partners

Phase 3 in Type 2 Diabetessmall molecule
Partial signal

NCT01529541 · Phase 3 · completed

The study randomly assigned an estimated 200 participants and used triple masking with sitagliptin as an active comparator. Its primary endpoint was the change in HbA1c, a surrogate measure, and no primary-outcome result is available to show whether the comparison was favorable.

Next expected readout: March 2027 · NCT07442006 (registry estimate)

Reported efficacy

The Change in HbA1c from baseline to week24 (0wk, 8wk, 16wk, 24wk): HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo. (met)

Result source: NCT01529528

Vildagliptin · Galvus

Marketed by Novartis and partners

Phase 3 in Type 2 Diabetessmall molecule
Partial signal

NCT00099866 · Phase 3 · completed

The study was randomized and double-blind, with an active metformin comparator and 570 participants. Its primary endpoint was the surrogate measure of HbA1c change, and because no trial results are posted, it cannot be determined whether the primary comparison was favorable.

Reported efficacy

Change from baseline in HbA1c at 52 weeks: At the study end, significant HbA(1c) reductions from baseline were seen with both vildagliptin (-1.0 +/- 0.1%, P < 0.001) and metformin (-1.4 +/- 0.1%, P < 0.001) (missed)

Result source: NCT00099866

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAnagliptinVildagliptin
HbA1c, change-0.5% vs 0.2%a−0.7 vs placeboanagliptin 200 mg · wk 24NCT01529528
2 other results
  • -0.5% vs 0.2% anagliptin 100 mg · wk 24 · Phase 3 · primary NCT01529528
  • -0.8% vs -0.8% wk 24 · Phase 3 · primary NCT01529541
7.2% vs 7.4%vs SU+Metforminwk 24 · n 19NCT01871558
3 other results
  • -1.0% vs -0.1% wk 12 · n 78 · Phase 4 · primary NCT02002221
  • -0.9% vs -0.6% wk 16 · n 115 · Phase 4 · primary NCT01882907
  • 1.9% vs 2.3% wk 12 · n 17 · Phase 4 · secondary NCT02007278
Body weight, change (kg)—Not posted · NCT01529528-0.3 vs 1.4vs SU+Metforminwk 24 · n 21NCT01871558
1 other result
  • -0.1 vs 0.7 wk 16 · n 115 · Phase 4 · secondary NCT01882907
HbA1c below 7%—Not posted · NCT01529528—Not posted · NCT00099866
Fasting plasma glucose, change—Not posted · NCT01529528-1.2 vs -0.0−1.2 vs placebowk 12 · n 78NCT02002221
3-point MACE (% with event)—Not posted · NCT01529528—Not posted · NCT00099866

HbA1c, change

Anagliptin
-0.5% vs 0.2%a−0.7 vs placeboanagliptin 200 mg · wk 24NCT01529528
2 other results
  • -0.5% vs 0.2% anagliptin 100 mg · wk 24 · Phase 3 · primary NCT01529528
  • -0.8% vs -0.8% wk 24 · Phase 3 · primary NCT01529541
Vildagliptin
7.2% vs 7.4%vs SU+Metforminwk 24 · n 19NCT01871558
3 other results
  • -1.0% vs -0.1% wk 12 · n 78 · Phase 4 · primary NCT02002221
  • -0.9% vs -0.6% wk 16 · n 115 · Phase 4 · primary NCT01882907
  • 1.9% vs 2.3% wk 12 · n 17 · Phase 4 · secondary NCT02007278

Body weight, change (kg)

Anagliptin
—Not posted · NCT01529528
Vildagliptin
-0.3 vs 1.4vs SU+Metforminwk 24 · n 21NCT01871558
1 other result
  • -0.1 vs 0.7 wk 16 · n 115 · Phase 4 · secondary NCT01882907

HbA1c below 7%

Anagliptin
—Not posted · NCT01529528
Vildagliptin
—Not posted · NCT00099866

Fasting plasma glucose, change

Anagliptin
—Not posted · NCT01529528
Vildagliptin
-1.2 vs -0.0−1.2 vs placebowk 12 · n 78NCT02002221

3-point MACE (% with event)

Anagliptin
—Not posted · NCT01529528
Vildagliptin
—Not posted · NCT00099866
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Anagliptin: 0 of 4 rows · Vildagliptin: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAnagliptinVildagliptin
Dropout rate—
10%a
NCT02007278 · Phase 4 · registry result, not featured evidence · combination
show 10 more results
0%
NCT01472432 · Phase 4 · registry result, not featured evidence
8.9%50mg once daily
NCT01766778 · Phase 4 · registry result, not featured evidence
6.6%50mg twice daily
NCT01766778 · Phase 4 · registry result, not featured evidence
7.5%
NCT01582243 · Phase 4 · registry result, not featured evidence · combination
2.6%
NCT02002221 · Phase 4 · registry result, not featured evidence
—
NCT01686932 · Phase 4 · registry result, not featured evidence
12%
NCT01882907 · Phase 4 · registry result, not featured evidence · add on
14.3%
NCT01871558 · Phase 3 · registry result, not featured evidence · combination
0%
NCT01822548 · Phase 3 · registry result, not featured evidence · combination
—50 mg
NCT01537120 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs—
—a
NCT02007278 · Phase 4 · registry result, not featured evidence · combination
show 10 more results
—
NCT01472432 · Phase 4 · registry result, not featured evidence
7.1%50mg once daily
NCT01766778 · Phase 4 · registry result, not featured evidence
6.6%50mg twice daily
NCT01766778 · Phase 4 · registry result, not featured evidence
2.5%
NCT01582243 · Phase 4 · registry result, not featured evidence · combination
2.6%
NCT02002221 · Phase 4 · registry result, not featured evidence
—
NCT01686932 · Phase 4 · registry result, not featured evidence
2.6%
NCT01882907 · Phase 4 · registry result, not featured evidence · add on
—
NCT01871558 · Phase 3 · registry result, not featured evidence · combination
—
NCT01822548 · Phase 3 · registry result, not featured evidence · combination
—50 mg
NCT01537120 · Phase 1 · registry result, not featured evidence
Serious AEs—
0%a
NCT02007278 · Phase 4 · registry result, not featured evidence · combination
show 10 more results
0%
NCT01472432 · Phase 4 · registry result, not featured evidence
3.6%50mg once daily
NCT01766778 · Phase 4 · registry result, not featured evidence
3.3%50mg twice daily
NCT01766778 · Phase 4 · registry result, not featured evidence
2.5%
NCT01582243 · Phase 4 · registry result, not featured evidence · combination
2.6%
NCT02002221 · Phase 4 · registry result, not featured evidence
4%
NCT01686932 · Phase 4 · registry result, not featured evidence
3.4%
NCT01882907 · Phase 4 · registry result, not featured evidence · add on
0%
NCT01871558 · Phase 3 · registry result, not featured evidence · combination
0%
NCT01822548 · Phase 3 · registry result, not featured evidence · combination
0%50 mg
NCT01537120 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs—
a
influenza like illness 15%
headache 10%
arthralgia 5%
NCT02007278 · Phase 4 · registry result, not featured evidence · combination
show 9 more results
50mg once daily
upper respiratory tract infection 14.3%
cough 3.6%
dizziness 3.6%
NCT01766778 · Phase 4 · registry result, not featured evidence
50mg twice daily
cough 3.3%
elevated liver function test 3.3%
hyperkalemia 3.3%
NCT01766778 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 12.5%
constipation 7.5%
vaginal infection 7.5%
NCT01582243 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 12.8% (placebo 14.1%)
hyperhidrosis 10.3% (placebo 2.6%)
hunger 9% (placebo 3.8%)
NCT02002221 · Phase 4 · registry result, not featured evidence
hypoglycaemia 26%
blood glucose decreased 8%
NCT01686932 · Phase 4 · registry result, not featured evidence
upper respiration infection 3.4%
common cold 2.6%
diarrhea 2.6%
NCT01882907 · Phase 4 · registry result, not featured evidence · add on
dyspepsia 4.8%
renal colic 4.8%
tooth abscess 4.8%
NCT01871558 · Phase 3 · registry result, not featured evidence · combination
hypoglycemia 0%
NCT01822548 · Phase 3 · registry result, not featured evidence · combination
50 mg
headache 17.4% (placebo 16.7%)
upper respiratory tract infection 17.4% (placebo 16.7%)
reaction site cannula 13% (placebo 20.8%)
NCT01537120 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Vildagliptin

Glucose MAGE 0.37 vs 0.35 Glimepiride and Metformin mmol/L @ 12wk
absolute value · mmol/L
NCT02007278 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from 6.68 mg/dL as posted
Glucose CONGA 0.16 vs 0.17 Glimepiride and Metformin mmol/L @ 12wk
absolute value · mmol/L
NCT02007278 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from 2.92 mg/dL as posted
Glucose Variability SD 0.08 vs 0.08 Glimepiride and Metformin mmol/L @ 12wk
absolute value · mmol/L
NCT02007278 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from 1.36 mg/dL as posted
HbA1c Decrease 0 3 100% (n=17) vs 100% (n=17) Glimepiride and Metformin @ 12wk
absolute value · percentage points
NCT02007278 · Phase 4 · registry result, not featured evidence · combination
All Ulcers Healed 15.1% (n=53) vs 30.2% (n=53) placebo @ 12wk
event count · % of participants
NCT01472432 · Phase 4 · registry result, not featured evidence · converted to % from 8 participants as posted
HbA1c -0.8% (n=49) @ 52wk50mg once daily
absolute change · percentage points
No placebo or comparator arm
NCT01766778 · Phase 4 · registry result, not featured evidence
show 11 more results
-1% (n=50) @ 52wk50mg twice daily
NCT01766778 · Phase 4 · registry result, not featured evidence
-0.6% (n=56) @ 13wk50mg once daily
NCT01766778 · Phase 4 · registry result, not featured evidence
-0.9% (n=61) @ 13wk50mg twice daily
NCT01766778 · Phase 4 · registry result, not featured evidence
-0.7% (n=56) @ 26wk50mg once daily
NCT01766778 · Phase 4 · registry result, not featured evidence
-0.9% (n=61) @ 26wk50mg twice daily
NCT01766778 · Phase 4 · registry result, not featured evidence
-0.7% (n=56) @ 39wk50mg once daily
NCT01766778 · Phase 4 · registry result, not featured evidence
-0.7% (n=61) @ 39wk50mg twice daily
NCT01766778 · Phase 4 · registry result, not featured evidence
-0.6% (n=56) @ 52wk50mg once daily
NCT01766778 · Phase 4 · registry result, not featured evidence
-0.6% (n=61) @ 52wk50mg twice daily
NCT01766778 · Phase 4 · registry result, not featured evidence
-0.82% (n=39) @ 24wk
NCT01582243 · Phase 4 · registry result, not featured evidence · combination
-0.82% (n=39) @ 12wk
NCT01582243 · Phase 4 · registry result, not featured evidence · combination
Fasting Plasma Glucose -0.9 mmol/L @ 13wk50mg once daily
absolute change · mmol/L
No placebo or comparator arm
NCT01766778 · Phase 4 · registry result, not featured evidence
show 9 more results
-1.3 mmol/L @ 13wk50mg twice daily
NCT01766778 · Phase 4 · registry result, not featured evidence
-1.2 mmol/L @ 26wk50mg once daily
NCT01766778 · Phase 4 · registry result, not featured evidence
-0.9 mmol/L @ 26wk50mg twice daily
NCT01766778 · Phase 4 · registry result, not featured evidence
-1.1 mmol/L @ 39wk50mg once daily
NCT01766778 · Phase 4 · registry result, not featured evidence
-1 mmol/L @ 39wk50mg twice daily
NCT01766778 · Phase 4 · registry result, not featured evidence
-0.9 mmol/L @ 52wk50mg once daily
NCT01766778 · Phase 4 · registry result, not featured evidence
-0.8 mmol/L @ 52wk50mg twice daily
NCT01766778 · Phase 4 · registry result, not featured evidence
-1.14 mmol/L @ 12wk*
NCT01582243 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -20.6 mg/dL as posted
-1.1 mmol/L @ 24wk*
NCT01582243 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -19.9 mg/dL as posted
PPG Change mg/dL -2.27 mmol/L @ 12wk
absolute change · mmol/L
No placebo or comparator arm
NCT01582243 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -40.9 mg/dL as posted
show 1 more result
-2.13 mmol/L @ 24wk*
NCT01582243 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -38.3 mg/dL as posted
Glucose MAGE -0.71 mmol/L @ 24wk
absolute change · mmol/L
No placebo or comparator arm
NCT01582243 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -12.8 mg/dL as posted
HbA1c 6 5 or Less 23% (n=78) vs 2% (n=78) placebo @ 12wk
responder rate · % of participants
Criterion 1 (n= 77, 78)
NCT02002221 · Phase 4 · registry result, not featured evidence
HbA1C Decrease at Least 0.5 62% (n=78) vs 20% (n=78) placebo @ 12wk
event count · % of participants
Criterion 5 (n= 78, 78)
NCT02002221 · Phase 4 · registry result, not featured evidence
Fasting Plasma Glucose -1.21 vs -0.02 placebo mmol/L @ 12wk
absolute change · mmol/L
NCT02002221 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -21.87 mg/dL as posted

+ 10 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anagliptin's landscape · Vildagliptin's landscape